TITLE

CV Therapeutics Shows Bought Deal Risk

AUTHOR(S)
Santini, Laura
PUB. DATE
August 2003
SOURCE
Investment Dealers' Digest;8/11/2003, Vol. 69 Issue 32, p14
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Reports on convertible deals between various healthcare companies and its impact on underwriters. Deal between Palo Alto, California-based biotech company CV Therapeutics Inc. and Citigroup Inc.; Prospects of the biotech company; Percentage decline in the share of the biotech company.
ACCESSION #
10610729

 

Related Articles

  • Move over, Net! Here come the biotech converts. Hahn, Avital Louria // Investment Dealers' Digest;02/28/2000, Vol. 66 Issue 9, p12 

    Reports popularity of biotechnology convertible bonds as of February 2000. Statistics comparing performance of Internet and biotechnology convertible bonds; Role of Human Genome Sciences Inc. in starting the trend; Increase in prices of convertible bonds.

  • Soaring convert market falls to earth with a thud. Hahn, Avital Louria // Investment Dealers' Digest;3/27/2000, Vol. 66 Issue 13, p5 

    Reports on the drop on convert issuance in the convertible deal market in the United States in March 2000 following a turnaround experienced in February 2000. Single deal for the week; Reasons for the decline; Impact of President Bill Clinton's remarks on genomic research on the stagnancy of...

  • More biotechs gamble on convertibles. Mitchell, Pete // Nature Biotechnology;Oct2001, Vol. 19 Issue 10, p894 

    Reports that biotechnology companies are turning to convertible issues as alternative sources of funding. Major biotechnology convertible issues/bonds trading on the U.S. market; Risk associated with convertibles; Status of the U.S. convertible market.

  • Biotechs Ahead of Pharma in '08 New Drug Approvals. Young, Donna // BioWorld Today;9/2/2008, Vol. 19 Issue 170, p1 

    The article reports on biologic and new molecular entities (NME) made by biotechnology companies. According to the author, Adolor Corporation's Entereg, Medicine Company's Cleviprex and CV Therapeutics Incorporated's Lexiscan were among the new molecular entities approved by the U.S. Food and...

  • Old Lane Invests $24Mn in KVK Energy & Infrastructure.  // EmergingMarketsNOW;7/2/2009, p6 

    The article reports on the move of Citigroup Inc.'s hedge fund Old Lane to invest 24 million U.S. dollars in KVK Energy & Infrastructure of Hyderabad, India-based KVK Group. It cites that the investment is expected to be in the form of compulsorily fully convertible debentures. The stake is also...

  • Astellas bids $1b for CV Therapeutics.  // TCE: The Chemical Engineer;Mar2009, Issue 813, p10 

    The article reports on the refusal of CV Therapeutics to accept the $1 billion (b) takeover offer by the Japanese pharmaceutical company Astellas. CV Therapeutics explained that the unsolicited bid did not favor the company. On the other hand, Astellas expressed its disappointment but will...

  • Biotechnology News Round-up.  // PharmaWatch: Biotechnology;Apr2007, Vol. 6 Issue 4, p2 

    The article offers news briefs related to the biotechnology industries. The controversial plan of Ventria Bioscience to implant the rice with human genes was given preliminary clearance by the U.S. government. CV Therapeutics Inc. drug Ranexa failed to prove its effectiveness in treating acute...

  • CV Therapeutics Files NDA For Regadenoson Use In Stress Tests. Boggs, Jennifer // BioWorld Today;5/16/2007, Vol. 18 Issue 95, p1 

    The article reports on the drug application for regadenoson filed by CV Therapeutics Inc. as a stress agent in myocardial perfusion imaging tests. The filing triggered a $7 million milestone from partner Astellas Pharma U.S. Inc. When the application is approved another $12 million will be...

  • OTHER NEWS TO NOTE.  // BioWorld Today;12/20/2007, Vol. 18 Issue 246, p2 

    This section offers news briefs related to the biotechnology industry across the world. Chairman Thomas Lynch has been appointed chief executive officer (CEO) at Amarin Corp. PLC in London, England. Axentis Pharma AG in Zurich, Switzerland, has gained exclusive licensing rights from aRigen...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics